discontinuation of anti-cgrp antibodies in non-responders
Published 2 years ago • 123 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:13
discontinuation and reinitiation of migraine treatment with gcrp mabs
-
1:55
treating migraines in patients not responding to cgrp monoclonal antibodies
-
8:29
real-world data on anti-cgrp monoclonal antibodies
-
4:05
for or against? anti-cgrp monoclonal antibodies as a first-line therapy for migraines
-
1:04
metabolism and response to anti-cgrp treatments in migraine
-
3:19
real-world studies show effectiveness of anti-cgrp mabs in difficult to treat patients with migraine
-
1:47
approval of anti-cgrp monoclonal antibodies for migraine in japan
-
1:47
anti-cgrp monoclonal antibodies for difficult to treat migraines: deliver trial
-
1:30
preliminary data on the use of anti-cgrp mabs in pediatric migraine
-
1:24
efficacy and safety of cgrp-directed antibodies in migraine
-
2:24
latest guidelines on anti-cgrp antibodies: first-line and long-term use
-
2:09
blocking cgrp in migraine patients: cardiovascular implications
-
1:26
update on ehf guideline for anti-cgrp antibodies for migraine prevention
-
1:37
predictive markers for cgrp-directed antibody treatment success in migraine
-
18:22
migraine prevention in the real world: exploring the role of anti-cgrp antibodies
-
11:55
migraine prevention in the real world: exploring the role of anti-cgrp antibodies
-
22:19
adverse events of anti-cgrp monoclonal antibodies for migraine - migraine masterclass: webinar 6
-
1:30
migraine: cgrp mabs efficacy measured over time
-
1:48
cgrp monoclonal antibody use in japan